top of page

Ousia Pharma

Paving the way for novel therapeutic strategies using peptide-drug-conjugates

About

Ousia, from the Greek for "essence"; Ousia Pharma emerged from a groundbreaking academic discovery at University of Copenhagen and rapidly evolved into a biotechnology company. We are pioneering innovative therapeutic strategies centered on peptide-drug conjugates to improve the lives of patients with cardiometabolic diseases.

Who are we?

Ousia Pharma ApS is a Danish biotech start-up focused on the development of novel peptide-drug conjugates for the treatment of metabolic diseases. We utilize a targeting approach in which peptides are used to deliver modulators of synaptic plasticity to appetite controlling regions of the brain.

The Team

Anders Bue.jpeg

Anders Bue Klein

Co-Founder, CEO, PhD in neuroscience Anders Bue Klein has a strong background in molecular metabolism and pharmocology with an impressive academic track record and has previously held an Assistant Professor position at the NNF Center for Basic Metabolic Research

  • LinkedIn
CC in colors.jpg

Christoffer Clemmensen

Co-Founder, CSO, PhD in metabolism, Group Leader (Clemmensen Lab) Christoffer Clemmensen leads an academic laboratory at the NNF Center for Basic Metabolic Research and has held various international positions at highly ranked research institutions

  • LinkedIn
JOP_headshot_edited.jpg

Jonas O. Petersen

Co-Founder, COO, PhD in medicinal chemistry Besides his PhD in medicinal chemistry, Jonas O. Petersen holds a Master of Engineering in Advancend Chemistry

  • LinkedIn

Board of Directors

Ian Laquian.jpeg

Ian Laquian

Chairman of the Board, MSc, MBA, serial entrepreneur, Kariya, Lophora, Avilex

  • LinkedIn
CC in colors.jpg

Christoffer Clemmensen

Co-Founder, CSO, PhD in metabolism, Group Leader (Clemmensen Lab) Christoffer Clemmensen leads an academic laboratory at the NNF Center for Basic Metabolic Research and has held various international positions at highly ranked research institutions

  • LinkedIn
Screenshot 2025-04-25 at 12.04.33.png

Otello Stampacchia

PhD in Molecular Biology (Geneva), MSc in Genetics (Pavia), serial investor (e.g. Omega Funds, Alpinvest, Lombard Odier, Goldman Sachs)

  • LinkedIn
Screenshot 2025-04-25 at 12.06.31.png

Menelas Pangalos

Former EVP R&D AstraZeneca, senior R&D roles at GSK & Wyeth, Fellow of the Royal Society, visiting prof (Kings, Manchester, Cambridge)

  • LinkedIn
Elisabeth Björk_headshot__IMG41971.jpg

Elisabeth Björk

MD, PhD, endocrinologist, formerly SVP AstraZeneca RD

  • LinkedIn
tomoe-steineck-T1Wru10gKhg-unsplash_edited.jpg

Mission

We are dedicated to developing effective and safe pharmacotherapies to improve the health and lives of people living with cardiometabolic disease.

bottom of page